Bioarchitech Overview
- Founded
-
2014

- Status
-
Private
- Employees
-
5

- Latest Deal Type
-
Angel
- Latest Deal Amount
-
$1.2M
- Investors
-
2
Bioarchitech General Information
Description
Operator of a biotechnology company intended to improve cancer therapy. The company engineers antibodies and other proteins, encoding them within the genome of an oncolytic virus that releases potent immunotherapy molecules into the surrounding tumor microenvironment, enabling physicians to orchestrate the destruction of tumor cells by the patient's own immune system.
Contact Information
Website
www.bioarchitech.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- BioEscalator, Innovation Building
- University of Oxford, Old Road Campus, Roosevelt Drive, Headington
- Oxford OX3 7FZ
- England, United Kingdom
+44 01865 000000
Bioarchitech Timeline
Bioarchitech Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Angel (individual) | 01-Feb-2022 | $1.2M | 00.000 | 000.00 | Completed | Generating Revenue |
6. Angel (individual) | 05-May-2021 | 00.00 | 00.000 | 00.000 | Completed | Generating Revenue |
5. Angel (individual) | 03-Apr-2019 | 00000 | 00000 | 000 | Completed | Generating Revenue |
4. Angel (individual) | 20-Oct-2017 | 00000 | 00000 | 00.000 | Completed | Generating Revenue |
3. Grant | 01-Dec-2016 | 00000 | 00000 | Completed | Generating Revenue | |
2. Early Stage VC | 17-Mar-2016 | $70.9K | $226K | 00000 | Completed | Generating Revenue |
1. Early Stage VC | 13-Aug-2015 | $155K | $155K | 00000 | Completed | Generating Revenue |
Bioarchitech Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.00 | |
Ordinary | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.00 | |
Ordinary | 00,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
Ordinary | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Ordinary | 00,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
Ordinary | 50,000 | $0.001355 | $1.36 | $1.36 | 1x | $1.36 | 3.79% | |
Ordinary | 165,750 | $0.001355 | $0.81 | $0.81 | 1x | $0.81 | 12.57% |
Bioarchitech Patents
Bioarchitech Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-201621665-D0 | Chimeric oncolytic virus | Inactive | 20-Dec-2016 | ||
GB-201522317-D0 | Chimeric oncolytic virus | Inactive | 17-Dec-2015 |
Bioarchitech Executive Team (4)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Kevin Maskell | Co-Founder & Research Director | ||
Hannah Chen | Co-Founder | ||
Geoffrey Hale Ph.D | Co-Founder, Managing Director & Board Member |
Bioarchitech Board Members (2)
Name | Representing | Role | Since |
---|---|---|---|
Geoffrey Hale Ph.D | Self | Co-Founder, Managing Director & Board Member | 000 0000 |
Bioarchitech Signals
Bioarchitech Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Innovate UK | Government | 000 0000 | 000000 0 | ||
Oxford Technology Management | Venture Capital | Minority | 000 0000 | 000000 0 |